OTCM
DTRK
Market cap230kUSD
Jul 07, Last price
0.18USD
1Q
-57.65%
Jan 2017
-98.15%
Name
DATATRAK International Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
DATATRAK International, Inc. delivers advanced technology and comprehensive service offerings tailored for the clinical research industry. Its flagship offering, DATATRAK ONE Unified Experience, is an integrated clinical enterprise platform empowering clinical professionals and service providers to efficiently design, execute, and oversee clinical trials. This robust suite features specialized modules such as UX CTMS 360 for trial planning and administration, UX Trial to streamline the design-to-deployment workflow, UX EDC & Medical Coding for secure data capture and delivery, and UX Randomization and Trial Supply Management for automating patient assignment and logistics. Further components include UX Patient Data Capture, UX Safety, and UX Training, which facilitates user education and certification tracking. Additionally, DATATRAK provides Clinical Consulting Services, offering expert training, ongoing support, a dedicated learning center, Software-as-a-Service hosting, adherence to industry standards, and bespoke trial design assistance. The company serves a diverse clientele, including contract research organizations, pharmaceutical and biotechnology firms, and medical device companies engaged in clinical studies. Founded in 1991, DATATRAK International, Inc. is headquartered in Mayfield Heights, Ohio.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||